Remote Endarterectomy Versus Supragenicular Bypass Surgery for Long Occlusions of the Superficial Femoral Artery: Medium-Term Results of a Randomized Controlled Trial (The REVAS Trial)

Background To investigate the optimal surgical treatment, remote superficial femoral artery endarterectomy (RSFAE) or supragenicular bypass, for Transatlantic Inter-Society Consensus (TASC) C and D lesions of the superficial femoral artery. Medium-term results will be presented. Methods The study randomized 116 patients, 61 to RSFAE and 55 to supragenicular bypass surgery. Indications for surgery were claudication in 77, rest pain in 21, or tissue loss in 18. Results Primary patency after 3 years of follow-up was 47% for RSFAE and 60% for bypass ( p  = 0.107), assisted primary patency was 63 and 69% ( p = 0.406), and secondary patency was 69 and 73% ( p = 0.541), respectively. For venous ( n = 25) and prosthetic grafts ( n = 30) at 3-year follow-up, primary patency was 65% and 56 versus 47% for RSFAE ( p = 0.143), assisted primary patency was 84% and 56 versus 63% for RSFAE ( p = 0.052), and secondary patency was 89% and 59 versus 69% for RSFAE ( p = 0.046), respectively. Limb salvage was 97% after RSFAE and 95% after bypass surgery ( p = 0.564). Conclusion RSFAE is a minimally invasive option for surgical repair of TASC C and D superficial femoral artery obstructions, with assisted primary and secondary patency rates comparable with bypass surgery. Venous bypass grafting is superior to both RSFAE and polytetrafluoroethylene grafting, but only 45% of patients had a sufficient saphenous vein available. If the saphenous vein is not applicable, RSFAE should be considered because it is less invasive and prosthetic graft material can be avoided.